HALOZYME THERAPEUTICS, INC. Debt Securities, Available-for-sale, Realized Gain (Loss)
HALOZYME THERAPEUTICS, INC. (HALO) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of -$28.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2026-08-06
- HALOZYME THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-12-31 was $244.00K.
- HALOZYME THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-09-30 was -$47.00K.
- HALOZYME THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-06-30 was -$26.00K.
- HALOZYME THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2025 was $171.00K, a 2342.86% increase from fiscal 2024.
- HALOZYME THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2024 was $7.00K.
- HALOZYME THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2023 was $0.00.
- HALOZYME THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2022 was -$1.73M.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$28.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $244.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $197.00K derived: sum of 2 quarters · filed 2026-02-17 | $171.00K derived: sum of 3 quarters · filed 2026-08-06 | $171.00K 10-K · filed 2026-02-17 |
| 2025-09-30 | -$47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$73.00K derived: sum of 2 quarters · filed 2026-08-06 | -$73.00K 10-Q · filed 2025-11-03 | -$73.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$26.00K 10-Q · filed 2026-08-06 | -$26.00K derived: sum of 3 quarters · filed 2026-08-06 | -$26.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-02-17 | $0.00 derived: sum of 3 quarters · filed 2026-02-17 | $0.00 derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $0.00 derived: sum of 2 quarters · filed 2026-02-17 | $0.00 derived: sum of 3 quarters · filed 2026-02-17 | $7.00K 10-K · filed 2026-02-17 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-03 | $7.00K 10-Q · filed 2025-11-03 | $7.00K derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $7.00K 10-Q · filed 2025-08-05 | $7.00K derived: sum of 3 quarters · filed 2026-02-17 | $7.00K derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $7.00K 10-Q · filed 2025-05-06 | $7.00K derived: sum of 2 quarters · filed 2026-02-17 | $7.00K derived: sum of 3 quarters · filed 2026-02-17 | $7.00K derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $0.00 derived: sum of 2 quarters · filed 2026-02-17 | $0.00 derived: sum of 3 quarters · filed 2026-02-17 | $0.00 10-K · filed 2026-02-17 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | $0.00 derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $0.00 derived: sum of 3 quarters · filed 2025-02-18 | $0.00 derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | $0.00 derived: sum of 2 quarters · filed 2025-02-18 | $0.00 derived: sum of 3 quarters · filed 2025-02-18 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $0.00 derived: sum of 2 quarters · filed 2025-02-18 | -$1.73M 10-K · filed 2025-02-18 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$1.73M 10-Q · filed 2023-11-06 | ||
| 2022-06-30 | -$1.73M 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $0.00 derived: sum of 2 quarters · filed 2024-02-20 | $0.00 10-K · filed 2024-02-20 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |